<p>MetLife, Inc.（纽约证券交易所：MET - 获取免费报告）已经收到了来自目前覆盖该公司的十三家评级公司的 “中等买入” 一致评级，Marketbeat 报告称。一位股票研究分析师给予该股票持有评级，而其他十二家公司则给予该公司买入评级。过去一年内覆盖该股票的经纪公司的平均一年目标价格为 84.54 美元。</p>
<ul>
<li>两只保险股准备大幅突破</li>
</ul>
<p>MET 已成为多份研究报告的热门话题。摩根大通将 MetLife 的股票价格目标从 86.00 美元下调至 85.00 美元，并在 8 月 19 日的报告中给予该股票 “超重” 评级。杰富瑞金融集团将 MetLife 的目标股价从 83.00 美元上调至 86.00 美元，并在 7 月 18 日的研究报告中给予该股票 “买入” 评级。美国银行将 MetLife 的股票价格目标从 99.00 美元下调至 96.00 美元，并在 8 月 1 日的研究报告中为该公司设定了 “买入” 评级。StockNews.com 在 9 月 10 日的报告中将 MetLife 的评级从 “买入” 调降至 “持有”。最后，花旗集团将 MetLife 的目标股价从 83.00 美元上调至 89.00 美元，并在 7 月 23 日的报告中给予该股票 “买入” 评级。</p>
<p><strong>查看我们关于 MetLife 的最新报告</strong></p>
<h2>MetLife 机构交易</h2>
<ul>
<li>MarketBeat 周度回顾 – 8/21 - 8/25</li>
</ul>
<p>一些机构投资者和对冲基金最近调整了他们对 MET 的持股。Gilbert &amp; Cook Inc. 在第四季度将其在 MetLife 的持股增加了 4.6%。Gilbert &amp; Cook Inc. 现在拥有 13,872 股 MetLife 的股票，价值 917,000 美元，在上个季度购买了额外的 605 股。Gryphon Financial Partners LLC 在第四季度购入了 MetLife 的新股，价值约 201,000 美元。Cambridge Investment Research Advisors Inc. 在第四季度增加了对 MetLife 的持股，持股增长了 7.8%。Cambridge Investment Research Advisors Inc. 现在拥有 78,499 股 MetLife 的股票，价值 5,191,000 美元，在该时期购入了额外的 5,707 股。美国银行 DE 分行在第四季度增加了对 MetLife 的持股，持股增长了 1.3%。美国银行 DE 现在拥有 106,391 股 MetLife 的股票，价值 7,036,000 美元，在上个季度购入了额外的 1,340 股。最后，野村资产管理有限公司在第四季度增加了对 MetLife 的持股，持股增长了 0.4%。野村资产管理有限公司现在拥有 185,735 股 MetLife 的股票，价值 12,283,000 美元，在该时期购入了额外的 816 股。89.81% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>MetLife 股价下跌 1.2%</h2>
<p>MetLife 股票周三开盘价为 80.45 美元。该股票的 50 天移动平均价格为 74.90 美元，200 天移动平均价格为 72.78 美元。MetLife 的一年最低价为 57.91 美元，最高价为 81.85 美元。该公司的市值为 572.1 亿美元，市盈率为 27.65，PEG 比率为 0.61，β系数为 1.04。公司的资产负债比为 0.56，流动比率为 0.16，速动比率为 0.16。</p>
<ul>
<li>这家保险巨头看起来已经准备好突破</li>
</ul>
<p>MetLife（纽约证券交易所：MET - 获取免费报告）最近发布了其季度财报，日期为 7 月 31 日。这家金融服务提供商在该季度报告中每股盈利为 2.28 美元，超过了每股盈利预期 2.13 美元。该公司在该季度的营收为 178.2 亿美元，相比分析师预期的 185.7 亿美元有所下降。MetLife 的净利润率为 4.23%，净资产收益率为 21.41%。与去年同期相比，MetLife 的当季营收增长了 7.2%。在去年同期的同一季度，该公司每股盈利为 1.94 美元。股票研究分析师预计，MetLife 今年将实现每股盈利 8.67 美元。</p>
<h2>MetLife 宣布股息</h2>
<p>该公司最近宣布了季度股息，股息于 9 月 10 日星期二支付。截至 8 月 6 日星期二持股人将获得 0.545 美元的股息。该股息的除息日为 8 月 6 日星期二。这代表年化基础上的 2.18 美元股息和 2.71% 的股息率。MetLife 的派息比率目前为 74.91%。</p>
<h2>关于 MetLife（获取免费报告）</h2>
<p>MetLife, Inc. 是一家提供保险、年金、雇员福利和资产管理服务的金融服务公司，业务遍布全球。它通过六个部门运营：退休与收入解决方案；团体福利；亚洲；拉丁美洲；欧洲、中东和非洲；以及 MetLife Holdings。该公司提供寿险、牙科保险、团体短期和长期残疾保险、个人残疾保险、宠物保险、意外身故和伤残保险、视力保险、意外和健康保险，以及预付法律计划；向雇主提供仅行政服务安排；以及普通和分户账户、合成保证利率合同，以及私人浮动利率融资协议。</p>
<h2>参见</h2>
<ul>
<li>我们喜欢的五只比 MetLife 更好的股票</li>
<li>如何找到盈利电话转录</li>
<li>Biohaven 股价因药物试验结果飙升：是时候入场了吗？</li>
<li>3 家值得购买的医疗保健股息股</li>
<li>AMD 是否对 NVIDIA 构成合法威胁？投资者应该关注什么</li>
<li>内幕交易是什么？你可以从内幕交易中学到什么</li>
<li>诺和诺德的挫折不会持续：一种改变游戏规则的药物出现</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1FVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1FVA"/></p>
<p><em>此即时新闻警报由叙事科技和来自 MarketBeat 的财务数据生成，以便向读者提供最快速和最准确的报道。本故事在发布前已经由 MarketBeat 的编辑团队进行了审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ CNBC 的 ‘预言家’ 发出紧急联邦储备警告（来自 Stansberry 研究）（广告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzAy?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzAy"/></p>
<h2>你现在是否应该投资$1,000 在大都会人寿？</h2>
<p>在考虑投资大都会人寿之前，您可能需要听听这个。</p>
<p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票，而大都会人寿不在名单上。</p>
<p>虽然大都会人寿目前在分析师中有一个&#34;中性买入&#34;评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

大都会人寿

<p>大都会人寿（MetLife, Inc.）（NYSE: MET）收到了来自十三位分析师的 “中等买入” 一致评级。其中一位分析师将其评为持有，而十二位将其评为买入。平均一年目标股价为 54 美元。最近的报告显示，各家公司对股价目标的调整存在分歧。机构投资者持有该股的比例为 89.81%。大都会人寿的股价开盘价为 45.45 美元，市值为 542.1 亿美元。公司每股盈利为 1.28 美元，超出预期，并宣布每股 0.545 美元的季度股息，股息率为 2.71%</p>

<p>MetLife, Inc. (NYSE:MET - Get Free Report) has received a consensus rating of &#34;Moderate Buy&#34; from the thirteen ratings firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $84.54.</p>
<ul>
<li>2 Insurance Stocks Poised For Major Breakouts</li>
</ul>
<div class="lb-trans"><p>MetLife, Inc.（纽约证券交易所：MET - 获取免费报告）已经收到了来自目前覆盖该公司的十三家评级公司的 “中等买入” 一致评级，Marketbeat 报告称。一位股票研究分析师给予该股票持有评级，而其他十二家公司则给予该公司买入评级。过去一年内覆盖该股票的经纪公司的平均一年目标价格为 84.54 美元。</p>
<ul>
<li>两只保险股准备大幅突破</li>
</ul>
</div><p>MET has been the topic of several research reports. Morgan Stanley dropped their price objective on shares of MetLife from $86.00 to $85.00 and set an &#34;overweight&#34; rating on the stock in a report on Monday, August 19th. Jefferies Financial Group upped their price target on MetLife from $83.00 to $86.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, July 18th. Bank of America reduced their price objective on MetLife from $99.00 to $96.00 and set a &#34;buy&#34; rating for the company in a research note on Thursday, August 1st. StockNews.com downgraded MetLife from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, September 10th. Finally, Citigroup increased their target price on MetLife from $83.00 to $89.00 and gave the stock a &#34;buy&#34; rating in a report on Tuesday, July 23rd.</p>
<div class="lb-trans"><p>MET 已成为多份研究报告的热门话题。摩根大通将 MetLife 的股票价格目标从 86.00 美元下调至 85.00 美元，并在 8 月 19 日的报告中给予该股票 “超重” 评级。杰富瑞金融集团将 MetLife 的目标股价从 83.00 美元上调至 86.00 美元，并在 7 月 18 日的研究报告中给予该股票 “买入” 评级。美国银行将 MetLife 的股票价格目标从 99.00 美元下调至 96.00 美元，并在 8 月 1 日的研究报告中为该公司设定了 “买入” 评级。StockNews.com 在 9 月 10 日的报告中将 MetLife 的评级从 “买入” 调降至 “持有”。最后，花旗集团将 MetLife 的目标股价从 83.00 美元上调至 89.00 美元，并在 7 月 23 日的报告中给予该股票 “买入” 评级。</p>
</div><p><strong>View Our Latest Report on MetLife</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 MetLife 的最新报告</strong></p>
</div><h2>Institutional Trading of MetLife</h2>
<ul>
<li>MarketBeat Week in Review – 8/21 - 8/25</li>
</ul>
<div class="lb-trans"><h2>MetLife 机构交易</h2>
<ul>
<li>MarketBeat 周度回顾 – 8/21 - 8/25</li>
</ul>
</div><p>A number of institutional investors and hedge funds have recently modified their holdings of MET. Gilbert &amp; Cook Inc. increased its position in shares of MetLife by 4.6% during the 4th quarter. Gilbert &amp; Cook Inc. now owns 13,872 shares of the financial services provider's stock valued at $917,000 after purchasing an additional 605 shares during the last quarter. Gryphon Financial Partners LLC purchased a new stake in MetLife during the fourth quarter worth about $201,000. Cambridge Investment Research Advisors Inc. raised its position in MetLife by 7.8% in the fourth quarter. Cambridge Investment Research Advisors Inc. now owns 78,499 shares of the financial services provider's stock worth $5,191,000 after acquiring an additional 5,707 shares during the period. US Bancorp DE boosted its stake in MetLife by 1.3% in the fourth quarter. US Bancorp DE now owns 106,391 shares of the financial services provider's stock valued at $7,036,000 after acquiring an additional 1,340 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. grew its position in shares of MetLife by 0.4% during the 4th quarter. Nomura Asset Management Co. Ltd. now owns 185,735 shares of the financial services provider's stock valued at $12,283,000 after acquiring an additional 816 shares during the period. 89.81% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近调整了他们对 MET 的持股。Gilbert &amp; Cook Inc. 在第四季度将其在 MetLife 的持股增加了 4.6%。Gilbert &amp; Cook Inc. 现在拥有 13,872 股 MetLife 的股票，价值 917,000 美元，在上个季度购买了额外的 605 股。Gryphon Financial Partners LLC 在第四季度购入了 MetLife 的新股，价值约 201,000 美元。Cambridge Investment Research Advisors Inc. 在第四季度增加了对 MetLife 的持股，持股增长了 7.8%。Cambridge Investment Research Advisors Inc. 现在拥有 78,499 股 MetLife 的股票，价值 5,191,000 美元，在该时期购入了额外的 5,707 股。美国银行 DE 分行在第四季度增加了对 MetLife 的持股，持股增长了 1.3%。美国银行 DE 现在拥有 106,391 股 MetLife 的股票，价值 7,036,000 美元，在上个季度购入了额外的 1,340 股。最后，野村资产管理有限公司在第四季度增加了对 MetLife 的持股，持股增长了 0.4%。野村资产管理有限公司现在拥有 185,735 股 MetLife 的股票，价值 12,283,000 美元，在该时期购入了额外的 816 股。89.81% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>MetLife Stock Down 1.2 %</h2>
<div class="lb-trans"><h2>MetLife 股价下跌 1.2%</h2>
</div><p>Shares of MetLife stock opened at $80.45 on Wednesday. The stock's 50-day moving average is $74.90 and its 200 day moving average is $72.78. MetLife has a one year low of $57.91 and a one year high of $81.85. The firm has a market cap of $57.21 billion, a price-to-earnings ratio of 27.65, a PEG ratio of 0.61 and a beta of 1.04. The company has a debt-to-equity ratio of 0.56, a current ratio of 0.16 and a quick ratio of 0.16.</p>
<ul>
<li>This Insurance Giant Looks Ready For A Breakout</li>
</ul>
<div class="lb-trans"><p>MetLife 股票周三开盘价为 80.45 美元。该股票的 50 天移动平均价格为 74.90 美元，200 天移动平均价格为 72.78 美元。MetLife 的一年最低价为 57.91 美元，最高价为 81.85 美元。该公司的市值为 572.1 亿美元，市盈率为 27.65，PEG 比率为 0.61，β系数为 1.04。公司的资产负债比为 0.56，流动比率为 0.16，速动比率为 0.16。</p>
<ul>
<li>这家保险巨头看起来已经准备好突破</li>
</ul>
</div><p>MetLife (NYSE:MET - Get Free Report) last released its quarterly earnings data on Wednesday, July 31st. The financial services provider reported $2.28 earnings per share for the quarter, beating the consensus estimate of $2.13 by $0.15. The company had revenue of $17.82 billion during the quarter, compared to analyst estimates of $18.57 billion. MetLife had a net margin of 4.23% and a return on equity of 21.41%. MetLife's revenue for the quarter was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.94 EPS. Equities research analysts anticipate that MetLife will post 8.67 EPS for the current year.</p>
<div class="lb-trans"><p>MetLife（纽约证券交易所：MET - 获取免费报告）最近发布了其季度财报，日期为 7 月 31 日。这家金融服务提供商在该季度报告中每股盈利为 2.28 美元，超过了每股盈利预期 2.13 美元。该公司在该季度的营收为 178.2 亿美元，相比分析师预期的 185.7 亿美元有所下降。MetLife 的净利润率为 4.23%，净资产收益率为 21.41%。与去年同期相比，MetLife 的当季营收增长了 7.2%。在去年同期的同一季度，该公司每股盈利为 1.94 美元。股票研究分析师预计，MetLife 今年将实现每股盈利 8.67 美元。</p>
</div><h2>MetLife Announces Dividend</h2>
<div class="lb-trans"><h2>MetLife 宣布股息</h2>
</div><p>The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 6th were paid a $0.545 dividend. The ex-dividend date of this dividend was Tuesday, August 6th. This represents a $2.18 dividend on an annualized basis and a dividend yield of 2.71%. MetLife's payout ratio is presently 74.91%.</p>
<div class="lb-trans"><p>该公司最近宣布了季度股息，股息于 9 月 10 日星期二支付。截至 8 月 6 日星期二持股人将获得 0.545 美元的股息。该股息的除息日为 8 月 6 日星期二。这代表年化基础上的 2.18 美元股息和 2.71% 的股息率。MetLife 的派息比率目前为 74.91%。</p>
</div><h2>About MetLife (Get Free Report</h2>
<div class="lb-trans"><h2>关于 MetLife（获取免费报告）</h2>
</div><p>MetLife, Inc, a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through six segments: Retirement and Income Solutions; Group Benefits; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements.</p>
<div class="lb-trans"><p>MetLife, Inc. 是一家提供保险、年金、雇员福利和资产管理服务的金融服务公司，业务遍布全球。它通过六个部门运营：退休与收入解决方案；团体福利；亚洲；拉丁美洲；欧洲、中东和非洲；以及 MetLife Holdings。该公司提供寿险、牙科保险、团体短期和长期残疾保险、个人残疾保险、宠物保险、意外身故和伤残保险、视力保险、意外和健康保险，以及预付法律计划；向雇主提供仅行政服务安排；以及普通和分户账户、合成保证利率合同，以及私人浮动利率融资协议。</p>
</div><h2>See Also</h2>
<ul>
<li>Five stocks we like better than MetLife</li>
<li>Where to Find Earnings Call Transcripts</li>
<li>Biohaven Stock Soars on Drug Trial Results: Time to Jump In?</li>
<li>3 Healthcare Dividend Stocks to Buy</li>
<li>Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch</li>
<li>What is Insider Trading? What You Can Learn from Insider Trading</li>
<li>Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges</li>
</ul>
<div class="lb-trans"><h2>参见</h2>
<ul>
<li>我们喜欢的五只比 MetLife 更好的股票</li>
<li>如何找到盈利电话转录</li>
<li>Biohaven 股价因药物试验结果飙升：是时候入场了吗？</li>
<li>3 家值得购买的医疗保健股息股</li>
<li>AMD 是否对 NVIDIA 构成合法威胁？投资者应该关注什么</li>
<li>内幕交易是什么？你可以从内幕交易中学到什么</li>
<li>诺和诺德的挫折不会持续：一种改变游戏规则的药物出现</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU1FVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&amp;Symbol=MET"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科技和来自 MarketBeat 的财务数据生成，以便向读者提供最快速和最准确的报道。本故事在发布前已经由 MarketBeat 的编辑团队进行了审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ CNBC’s ‘Prophet’ issues urgent Fed warning (From Stansberry Research)(Ad)</p>
<div class="lb-trans"><p>→ CNBC 的 ‘预言家’ 发出紧急联邦储备警告（来自 Stansberry 研究）（广告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MzAy" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9302&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in MetLife right now?</h2>
<div class="lb-trans"><h2>你现在是否应该投资$1,000 在大都会人寿？</h2>
</div><p>Before you consider MetLife, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资大都会人寿之前，您可能需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MetLife wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高、表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票，而大都会人寿不在名单上。</p>
</div><p>While MetLife currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然大都会人寿目前在分析师中有一个&#34;中性买入&#34;评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

大都会人寿公司（纽约证券交易所代码：MET）被分析师一致评级为 “适度买入”